Risk of myocardial infarction with increasing quintile of factor VIIIc overall and factor IXc
. | Patients . | Control subjects . | OR (95% CI)* . | OR (95% CI)† . | OR (95% CI)‡ . |
|---|---|---|---|---|---|
| Factor VIIIc | |||||
| Overall, N | 560 | 645 | |||
| 50-93 IU/dL | 86 | 137 | 1∥ | 1∥ | 1∥ |
| 94-110 IU/dL | 102 | 122 | 1.4 (0.9-2.0) | 1.4 (0.9-2.1) | 2.1 (1.1-3.9) |
| 111-130 IU/dL | 137 | 134 | 1.7 (1.2-2.4) | 1.9 (1.3-2.9) | 1.8 (1.0-3.5) |
| 131-152 IU/dL | 134 | 125 | 1.8 (1.3-2.7) | 2.4 (1.6-3.6) | 2.6 (1.3-5.0) |
| 153-277 IU/dL | 101 | 127 | 1.4 (0.9-2.0) | 1.5 (1.0-2.4) | 1.6 (0.8-3.4) |
| Younger than 50 y, no. | 154 | 160 | |||
| 50-93 IU/dL | 39 | 50 | 1∥ | 1∥ | 1∥ |
| 94-110 IU/dL | 37 | 29 | 1.7 (0.9-3.3) | 1.6 (0.8-3.3) | 1.7 (0.6-4.5) |
| 111-130 IU/dL | 33 | 42 | 1.1 (0.6-2.0) | 1.1 (0.5-2.0) | 0.8 (0.3-2.2) |
| 131-152 IU/dL | 26 | 19 | 1.8 (0.9-3.8) | 1.9 (0.9-4.1) | 2.1 (0.7-6.4) |
| 153-277 IU/dL | 19 | 20 | 1.2 (0.6-2.6) | 1.0 (0.4-2.2) | 0.8 (0.2-3.0) |
| Factor IXc§ | |||||
| Overall, N | 420 | 640 | |||
| 12%-82% | 40 | 130 | 1∥ | 1∥ | 1∥ |
| 83%-91% | 91 | 143 | 2.5 (1.6-3.9) | 2.5 (1.6-3.9) | 2.7 (1.4-5.3) |
| 92%-97% | 93 | 122 | 3.0 (1.9-4.8) | 3.0 (1.9-4.9) | 3.0 (1.5-6.2) |
| 98%-104% | 105 | 134 | 3.1 (2.0-4.9) | 3.2 (2.0-5.1) | 3.7 (1.8-7.8) |
| 105%-135% | 91 | 111 | 3.2 (2.0-5.1) | 3.3 (2.0-5.4) | 2.9 (1.3-6.8) |
| Younger than 50 y, no. | 119 | 158 | |||
| 12%-82% | 17 | 69 | 1∥ | 1∥ | 1∥ |
| 83%-91% | 22 | 32 | 2.6 (1.2-5.6) | 2.6 (1.2-5.6) | 2.0 (0.6-6.1) |
| 92%-97% | 26 | 23 | 4.1 (1.9-9.0) | 4.8 (2.1-10.9) | 5.5 (1.7-17.5) |
| 98%-104% | 32 | 17 | 7.0 (3.2-15.6) | 9.2 (3.9-21.8) | 9.5 (2.7-33.2) |
| 105%-135% | 22 | 17 | 5.0 (2.2-11.4) | 6.2 (2.6-14.9) | 3.1 (0.7-13.5) |
. | Patients . | Control subjects . | OR (95% CI)* . | OR (95% CI)† . | OR (95% CI)‡ . |
|---|---|---|---|---|---|
| Factor VIIIc | |||||
| Overall, N | 560 | 645 | |||
| 50-93 IU/dL | 86 | 137 | 1∥ | 1∥ | 1∥ |
| 94-110 IU/dL | 102 | 122 | 1.4 (0.9-2.0) | 1.4 (0.9-2.1) | 2.1 (1.1-3.9) |
| 111-130 IU/dL | 137 | 134 | 1.7 (1.2-2.4) | 1.9 (1.3-2.9) | 1.8 (1.0-3.5) |
| 131-152 IU/dL | 134 | 125 | 1.8 (1.3-2.7) | 2.4 (1.6-3.6) | 2.6 (1.3-5.0) |
| 153-277 IU/dL | 101 | 127 | 1.4 (0.9-2.0) | 1.5 (1.0-2.4) | 1.6 (0.8-3.4) |
| Younger than 50 y, no. | 154 | 160 | |||
| 50-93 IU/dL | 39 | 50 | 1∥ | 1∥ | 1∥ |
| 94-110 IU/dL | 37 | 29 | 1.7 (0.9-3.3) | 1.6 (0.8-3.3) | 1.7 (0.6-4.5) |
| 111-130 IU/dL | 33 | 42 | 1.1 (0.6-2.0) | 1.1 (0.5-2.0) | 0.8 (0.3-2.2) |
| 131-152 IU/dL | 26 | 19 | 1.8 (0.9-3.8) | 1.9 (0.9-4.1) | 2.1 (0.7-6.4) |
| 153-277 IU/dL | 19 | 20 | 1.2 (0.6-2.6) | 1.0 (0.4-2.2) | 0.8 (0.2-3.0) |
| Factor IXc§ | |||||
| Overall, N | 420 | 640 | |||
| 12%-82% | 40 | 130 | 1∥ | 1∥ | 1∥ |
| 83%-91% | 91 | 143 | 2.5 (1.6-3.9) | 2.5 (1.6-3.9) | 2.7 (1.4-5.3) |
| 92%-97% | 93 | 122 | 3.0 (1.9-4.8) | 3.0 (1.9-4.9) | 3.0 (1.5-6.2) |
| 98%-104% | 105 | 134 | 3.1 (2.0-4.9) | 3.2 (2.0-5.1) | 3.7 (1.8-7.8) |
| 105%-135% | 91 | 111 | 3.2 (2.0-5.1) | 3.3 (2.0-5.4) | 2.9 (1.3-6.8) |
| Younger than 50 y, no. | 119 | 158 | |||
| 12%-82% | 17 | 69 | 1∥ | 1∥ | 1∥ |
| 83%-91% | 22 | 32 | 2.6 (1.2-5.6) | 2.6 (1.2-5.6) | 2.0 (0.6-6.1) |
| 92%-97% | 26 | 23 | 4.1 (1.9-9.0) | 4.8 (2.1-10.9) | 5.5 (1.7-17.5) |
| 98%-104% | 32 | 17 | 7.0 (3.2-15.6) | 9.2 (3.9-21.8) | 9.5 (2.7-33.2) |
| 105%-135% | 22 | 17 | 5.0 (2.2-11.4) | 6.2 (2.6-14.9) | 3.1 (0.7-13.5) |
Adjusted for age.
Adjusted for age and either factor IX (excluding anticoagulant users) or factor VIIIc, each as a continuous factor.
Adjusted for age, either factor IX (excluding anticoagulant users) or factor VIIIc each as a continuous factor; total cholesterol, HDL-cholesterol, and triglyceride levels; quetelet index; smoking; alcohol use; and diabetes, excluding individuals having hypertension.
Excludes anticoagulant users.
Reference group.